FORM 4

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|
| Estimated average burden |           |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| affirmative defen<br>10b5-1(c). See I | ise conditions of Rule instruction 10. |                  |   |   |  |  |  |  |
|---------------------------------------|--|------------------|---|---|--|--|--|--|
| 1. Name and Addre                     | ess of Reporting Per                   | son*             | 2. Issuer Name and Ticker or Trading Symbol Inhibikase Therapeutics, Inc. [ IKT ] | S. Relationship of Reporting Person(s) to Issuer (Check all applicable)      X Director 10% Owner |  |  |  |  |
|                                       |  | ` ,              | 3. Date of Earliest Transaction (Month/Day/Year) 01/03/2025                       | Officer (give title Other (specify below) below)  |  |  |  |  |
| 3350 RIVERW                           | OOD PARKWA                             | Y SE, SUITE 1900 | 4. If Amendment, Date of Original Filed (Month/Day/Year)                          | Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person |  |  |  |  |
| (Street)                              |  |                  |   | Form filed by More than One Reporting Person  |  |  |  |  |
| ATLANTA                               | GA                                     | 30339            |   | Tom med by wore than One Reporting Person   |  |  |  |  |
| (City)                                | (State)                                | (Zip)            |   |   |  |  |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 1 ' ' | Execution Date, Transaction |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |       | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | Beneficial<br>Ownership |
|---------------------------------|--|-------|-----------------------------|---|--|---------------|-------|--|---|-------------------------|
|                                 |  |       | Code                        | v | Amount   | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)                                     |   | (Instr. 4)              |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (In<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and<br>5) |     |                     |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | derivative Securities Beneficially Owned Following Reported | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|---------------------------------|---|--|-----|---------------------|--------------------|--|----------------------------------|---|---|--|--|
|   |   |  |   | Code                            | v | (A)  | (D) | Date<br>Exercisable | Expiration<br>Date | Title  | Amount or<br>Number of<br>Shares |   | Transaction(s)<br>(Instr. 4)                                |  |  |
| Stock Option<br>(Right to Buy)                      | \$1.26  | 01/03/2025                                 |   | A                               |   | 344,452  |     | (1)                 | 01/03/2035         | Common<br>Stock  | 344,452                          | \$0   | 344,452   | D  |  |
| Stock Option<br>(Right to Buy)                      | \$1.45  | 01/03/2025                                 |   | A                               |   | 172,191  |     | (2)                 | 01/03/2035         | Common<br>Stock  | 172,191                          | \$0   | 172,191   | D  |  |
| Stock Option<br>(Right to Buy)                      | \$1.58  | 01/03/2025                                 |   | A                               |   | 316,647  |     | (3)                 | 01/03/2035         | Common<br>Stock  | 316,647                          | \$0   | 316,647   | D  |  |

#### **Explanation of Responses:**

- 1. The options vested and became exercisable on October 9, 2024.
- 2. The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.
- 3. The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.

/s/ Milton H. Werner, attorney-infact 01/07/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.